CASTLEFORD, England, June 14, 2012 /PRNewswire/ --
Teva UK Limited is pleased to launch (Oroeze) Benzydamine 0.15% w/v Oromucosal spray.
(Oroeze) Benzydamine Oromucosal spray is a version of brand leader's Difflam® (Benzydamine) from Meda Pharmaceuticals. The Oroeze MA Holder is Focus Pharmaceuticals.
It is indicated as a locally acting analgesic and anti-inflammatory treatment for the throat and mouth. It is especially useful for the relief of pain in traumatic conditions such as following tonsillectomy or the use of a naso-gastric tube; dental surgery.
This product is available immediately in the award-winning Teva 360 livery, as follows:
Product (Oroeze) Benzydamine 0.15% w/v Oromucosal Spray x 1 Pack size 30ml x 1 Strength 0.15% w/v Brand price GBP3.63 Initial Teva retail price GBP3.50
Kim Innes, Commercial Director at Teva, said: "As the leading supplier of generic medicines and with the widest portfolio of our competitors, Teva continues with strong product launches and patent expiries. We've already launched eighteen new products this year including ten on day-one of patent expiry."
New or existing customers can order through their local Teva Territory Sales Manager, by completing the online form, or calling on 0800 085 8621
To find out more about Teva UK Limited, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email email@example.com.
SOURCE Teva UK Ltd